# The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome

> **NCT00759291** · PHASE2,PHASE3 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 40 (actual)

## Conditions studied

- Metabolic Syndrome

## Interventions

- **DRUG:** acipimox
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00759291
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04-01
- **Primary completion:** 2017-12-01
- **Final completion:** 2017-12-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00759291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00759291, "The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00759291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*